Outcome of patients with Philadelphia chromosome-positive chronic myelogenous leukemia post-imatinib mesylate failure

Hagop Kantarjian, Susan O'Brien, Moshe Talpaz, Gautam Borthakur, Farhad Ravandi, Stefan Faderl, Srdan Verstovsek, Mary Beth Rios, Jianqin Shan, Francis Giles, Jorge Cortes

Research output: Contribution to journalArticle

70 Scopus citations


BACKGROUND. The prognosis of patients with chronic myelogenous leukemia (CML) after failure of imatinib mesylate therapy is not well documented. METHODS. The outcome of 420 patients with CML post-imatinib failure (resistance-recurrence in 374; toxicities in 46) were reviewed in relation to survival, overall, and by different therapies. RESULTS. The estimated 3-year survival rates were 72% in 88 patients who progressed in chronic phase, 30% in 130 patients who progressed in accelerated phase, 7% in 156 patients who progressed in blastic phase, and 75% in 37 patients in chronic phase with imatinib intolerance. Survival in chronic phase was better when subsequent therapy was nilotinib or dasatinib vs allogeneic stem cell transplant vs others (estimated 2-year survival rates 100% vs 72% vs 67%; P = .01), but not in accelerated-blastic phase. CONCLUSIONS. Prognosis post-imatinib failure in chronic phase is reasonable; it is poor if the CML phase post-imatinib failure is accelerated or blastic.

Original languageEnglish (US)
Pages (from-to)1556-1560
Number of pages5
Issue number8
Publication statusPublished - Apr 15 2007
Externally publishedYes



  • Chronic myelogenous leukemia
  • Imatinib mesylate failure
  • Prognosis

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this